- As Moderna Inc (NASDAQ: MRNA) approaches to manufacture almost one million doses a day, the company has proposed filling COVID-19 vaccine vials with additional doses of up to 15 versus 10 currently to ease the manufacturing crunch, Reuters reports.
- Last week CNBC reported that Moderna had asked the FDA to fill its COVID-19 vaccine vials with up to five additional doses.
- “Additional doses would help address capacity constraints, noting that “beyond the amount of drug product available, is how many vials you can fill in a given period of time,” said Moderna’s President, Stephen Hoge.
- “Moderna would need to have further discussions with the FDA to assure the agency’s comfort with this approach before implementing,” the company said.
- Yesterday, BofA Securities’ analyst downgraded the company’s stock from Neutral to Underperform and maintained a $150 price target, citing that MRNA shares have increased to difficult levels to justify a fundamental basis.
- Price Action: MRNA shares are higher by 2.15% at $160.86 in the pre-market session on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in